Hasil Pencarian - Judit Demeter

  • Menampilkan 1 - 16 hasil dari 16
Perbaiki Hasil
  1. 1
    Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption

    Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption oleh Judit Demeter, Julia Weisinger, Zsolt Nagy

    Diterbitkan 2021-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    BCR activated CLL B cells use both CR3 (CD11b/CD18) and CR4 (CD11c/CD18) for adhesion while CR4 has a dominant role in migration towards SDF-1.

    BCR activated CLL B cells use both CR3 (CD11b/CD18) and CR4 (CD11c/CD18) for adhesion while CR4 has a dominant role in migration towards SDF-1. oleh Zsuzsa Nagy-Baló, Richárd Kiss, Judit Demeter, Csaba Bödör, Zsuzsa Bajtay, Anna Erdei

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary

    Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary oleh Peter Batar, Hussain Alizadeh, Gyorgy Rokszin, Zsolt Abonyi-Toth, Zsolt Abonyi-Toth, Judit Demeter

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary

    Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungar... oleh Peter Batar, Hussain Alizadeh, Gyorgy Rokszin, Zsolt Abonyi-Toth, Zsolt Abonyi-Toth, Judit Demeter

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University

    Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology... oleh Kata Ferenczi, Zsófia Flóra Nagy, Ildikó Istenes, Hanna Eid, Csaba Bödör, Botond Timár, Judit Demeter

    Diterbitkan 2023-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Case Report: Development of Diffuse Large B Cell Lymphoma a Long Time After Hairy Cell Leukemia

    Case Report: Development of Diffuse Large B Cell Lymphoma a Long Time After Hairy Cell Leukemia oleh Zsófia F. Nagy, Kata Ferenczi, Ildikó Istenes, Hanna Eid, Csaba Bödör, Botond Timár, Judit Demeter

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival

    Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival oleh Ádám Nagy, Ágnes Ősz, Jan Budczies, Szilvia Krizsán, Gergely Szombath, Judit Demeter, Csaba Bödör, Balázs Győrffy

    Diterbitkan 2019-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Case report: Comprehensive clinical, pathological and genetic investigations to decipher the background of cyclic thrombocytopenia

    Case report: Comprehensive clinical, pathological and genetic investigations to decipher the background of cyclic thrombocytopenia oleh Zsófia Flóra Nagy, Kristóf Árvai, Péter Lakatos, Ildikó Beke Debreceni, Balázs Szili, Ildikó Istenes, Csaba Bödör, Judit Demeter

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study

    Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study oleh Christopher R. Flowers, Matthew J. Matasar, Alex F. Herrera, Mark Hertzberg, Sarit Assouline, Judit Demeter, Andrew McMillan, Amitkumar Mehta, Stephen Opat, Marek Trnňný, Lisa Musick, Jamie Hirata, Annie Yang, Laurie H. Sehn

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry

    Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry oleh Ferenc Takács, Ferenc Takács, Lili Kotmayer, Ágnes Czeti, Gábor Szalóki, Tamás László, Gábor Mikala, Ágnes Márk, András Masszi, Péter Farkas, Márk Plander, Júlia Weisinger, Judit Demeter, Sándor Fekete, László Szerafin, Beáta Margit Deák, Erika Szaleczky, Adrienn Sulák, Zita Borbényi, Gábor Barna

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    P1245: PARALLEL TESTING OF LIQUID BIOPSY (CTDNA) AND TISSUE BIOPSY SAMPLES REVEALS A HIGHER FREQUENCY OF TARGETABLE EZH2 MUTATIONS IN FOLLICULAR LYMPHOMA

    P1245: PARALLEL TESTING OF LIQUID BIOPSY (CTDNA) AND TISSUE BIOPSY SAMPLES REVEALS A HIGHER FREQUENCY OF TARGETABLE EZH2 MUTATIONS IN FOLLICULAR LYMPHOMA oleh Bence Bátai, Ákos Nagy, Laura Kiss, Stefánia Gróf, Péter Attila Király, Ádám Jóna, Judit Demeter, Hermina Santa, Arpad Batai, Piroska Pettendi, Tamás Szendrei, Márk Béla Plander, Gábor Kőrösmezey, Hussain Alizadeh, Béla Kajtár, Gábor Méhes, László Krenács, Botond Timár, Judit Csomor, Erika Tóth, Tamás Schneider, Gabor Mikala, András Matolcsy, Donat Alpar, András Masszi, Csaba Bödör

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Landscape of <i>BCL2</i> Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

    Landscape of <i>BCL2</i> Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax oleh Lili Kotmayer, Tamás László, Gábor Mikala, Richárd Kiss, Luca Lévay, Lajos László Hegyi, Stefánia Gróf, Tibor Nagy, Gábor Barna, Péter Farkas, Júlia Weisinger, Zsolt Nagy, Alexandra Balogh, Tamás Masszi, Judit Demeter, Adrienn Sulák, Zoltán Kohl, Hussain Alizadeh, Miklós Egyed, Piroska Pettendi, Lajos Gergely, Márk Plander, Zsolt Pauker, András Masszi, András Matolcsy, Róbert Szász, Csaba Bödör, Donát Alpár

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial

    Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial oleh Hartmut Döhner, Argiris Symeonidis, Dries Deeren, Judit Demeter, Miguel A. Sanz, Achilles Anagnostopoulos, Jordi Esteve, Walter Fiedler, Kimmo Porkka, Hee-Je Kim, Je-Hwan Lee, Kensuke Usuki, Stefano D'Ardia, Chul Won Jung, Olga Salamero, Heinz-August Horst, Christian Recher, Philippe Rousselot, Irwindeep Sandhu, Koen Theunissen, Felicitas Thol, Konstanze Döhner, Veronica Teleanu, Daniel J. DeAngelo, Tomoki Naoe, Mikkael A. Sekeres, Valerie Belsack, Miaomiao Ge, Tillmann Taube, Oliver G. Ottmann

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION

    PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION oleh Tamás László, Lili Kotmayer, Lajos Hegyi, Stefánia Gróf, Béla Kajtár, Alexandra Balogh, Júlia Weisinger, Tamás Masszi, Zsolt Nagy, Judit Demeter, Péter Farkas, Ildikó Istenes, Róbert Szász, Lajos Gergely, Adrienn Sulák, Zita Borbényi, Dóra Lévai, Tamás Schneider, Erika Szaleczky, Piroska Pettendi, Emese Bodai, László Szerafin, László Rejtő, Árpád Bátai, Mária Ágnes Dömötör, Hermina Sánta, Márk Plander, Tamás Szendrei, Péter Ilonczai, Aryan Hamed, Zsolt Lázár, Zsolt Pauker, Gáspár Radványi, Adrienn Kiss, Gábor Körösmezey, János Jakucs, Péter János Dombi, Zsófia Simon, Zsolt Klucsik, Mihály Gurzó, Márta Tiboly, Tímea Vidra, András Bors, Hajnalka Andrikovics, Miklós Egyed, Tamás Székely, András Masszi, András Matolcsy, Donát Alpár, Csaba Bödör

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

    Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia oleh Farhad Ravandi, Robert J. Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema A. Bhat, James S. Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sasha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E. Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B. Johnston, Jeffrey Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A. Parikh, Jae H. Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A. Rogers, Alan Saven, John F. Seymour, Tamar Tadmor, Martin S. Tallman, Constantine S. Tam, Philip A. Thompson, Xavier Troussard, Clive S. Zent, Thorsten Zenz, Pier Luigi Zinzani, Bernhard Wörmann, Kanti Rai, Michael Grever

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Low‐burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation

    Low‐burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation oleh Tamás László, Lili Kotmayer, Viktória Fésüs, Lajos Hegyi, Stefánia Gróf, Ákos Nagy, Béla Kajtár, Alexandra Balogh, Júlia Weisinger, Tamás Masszi, Zsolt Nagy, Péter Farkas, Judit Demeter, Ildikó Istenes, Róbert Szász, Lajos Gergely, Adrienn Sulák, Zita Borbényi, Dóra Lévai, Tamás Schneider, Piroska Pettendi, Emese Bodai, László Szerafin, László Rejtő, Árpád Bátai, Mária Á Dömötör, Hermina Sánta, Márk Plander, Tamás Szendrei, Aryan Hamed, Zsolt Lázár, Zsolt Pauker, Gáspár Radványi, Adrienn Kiss, Gábor Körösmezey, János Jakucs, Péter J Dombi, Zsófia Simon, Zsolt Klucsik, Mihály Gurzó, Márta Tiboly, Tímea Vidra, Péter Ilonczai, András Bors, Hajnalka Andrikovics, Miklós Egyed, Tamás Székely, András Masszi, Donát Alpár, András Matolcsy, Csaba Bödör

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: